Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | FTSE 250 movers: Playtech on the rise; PureTech Health slips | 5 | Sharecast | ||
Do | PureTech Health plc - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
Do | PureTech Health plc - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
Do | Puretech Health operating losses narrow in 'landmark year' | 1 | Sharecast | ||
Do | PureTech Announces Annual Results for Year Ended December 31, 2023 | 59 | Business Wire | BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance... ► Artikel lesen | |
Do | PureTech touts "momentum" as grants shrivel but annual loss narrows | 1 | Alliance News | ||
Do | PureTech Health PLC - Final Results | - | RNS | ||
18.04. | PureTech Health PLC - Notice of Results | 1 | RNS | ||
16.04. | PureTech Health PLC - PRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024 | - | RNS | ||
11.04. | US FDA hands fast track to PureTech head and neck cancer treatment | 2 | Alliance News | ||
11.04. | PureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck Cancers | - | RTTNews | ||
11.04. | PureTech Health PLC - FDA Grants PRTC's LYT-200 Fast Track Designation | - | RNS | ||
10.04. | PureTech Startup Gets $100M to Try For Success Where Sage & Others Fall Short in Depression | 2 | MedCity News | ||
09.04. | PureTech launches Seaport, hoping to create Karuna 2.0 | 1 | BioPharma Dive | ||
09.04. | PureTech Health CEO Zohar moves to head-up portfolio firm Seaport | 1 | Alliance News | ||
09.04. | PureTech Health plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
09.04. | PureTech founder steps down as CEO to lead SeaPort spin-off | 2 | Sharecast | ||
09.04. | PureTech Names Bharatt Chowrira CEO As Daphne Zohar Turns CEO Of Newly Launched Seaport Therapeutics | - | RTTNews | ||
09.04. | PureTech Health PLC - PRTC Launches Seaport w/ $100M; Leadership Changes | 1 | RNS | ||
19.03. | PureTech announces $100M capital return through tender offer | 4 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 65,65 | -3,24 % | ÜBERNAHME-FIEBER bei Biotech-Aktien! Evotec, Bayer, Vidac Pharma - wer folgt auf Morphosys? | Im Biotech-Sektor herrscht Übernahme-Fieber. Zuletzt hat Genmab den Kauf von ProfoundBio, das US-Biotech-Unternehmen entwickelt Medikamente gegen Eierstock- und Gebärmutterschleimhautkrebs, für 1,8... ► Artikel lesen | |
EVOTEC | 9,625 | +4,22 % | EQS-News: Evotec SE: Bayer und Evotec vereinbaren Forschungskollaboration in der Präzisionskardiologie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Bayer und Evotec vereinbaren Forschungskollaboration in der Präzisionskardiologie
30.04.2024 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
QIAGEN | 39,145 | +0,99 % | Minimale Kursveränderung bei Qiagen NV-Aktie (38,75 €) | CODE Der jüngste Kurs betrug 38,75 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Qiagen NV-Aktie. Die Aktie weist aktuell nur einen minimalen Kursabschlag von 0,40 Prozent auf.... ► Artikel lesen | |
JANUX THERAPEUTICS | 56,08 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
SPRINGWORKS THERAPEUTICS | 46,450 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
IMMUNOVANT | 27,490 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
CABALETTA BIO | 10,480 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
VERA THERAPEUTICS | 41,380 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
NUVALENT | 67,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
ARCELLX | 51,11 | 0,00 % | Should You Be Bullish on Arcellx (ACLX)? | ||
CULLINAN THERAPEUTICS | 27,120 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
BIONTECH | 83,85 | +1,76 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für das Biotechnologieunternehmen Biontech in einem Ausblick auf den Quartalsbericht mit einem Kursziel von 95 US-Dollar auf... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
BEAM THERAPEUTICS | 22,050 | +3,13 % | Expert Ratings For Beam Therapeutics | ||
ARVINAS | 31,900 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |